Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides
摘要:
A series of 6-substituted 2',3'-dideoxypurine ribofuranosides (ddP) was enzymatically synthesized with live E. coli in an effort to enhance the lipophilicity of this class of anti-human immunodeficiency virus (HIV) compounds and thereby facilitate drug delivery into the central nervous system. All 6-halo-substituted ddPs were substantially more lipophilic, as defined by their octanol-water partition coefficient (P), than their nonhalogenated congeners 2',3'-dideoxyinosine (ddI) or 2',3'-dideoxyguanosine (ddG). For this class of compounds, log P's ranged from +0.5 to -1.2 in the following order: 6-iodo, 2-amino-6-iodo > 6-bromo, 2-amino-6-bromo > 6-chloro, 2-amino-6-chloro > 6-fluoro, 2-amino-6-fluoro >> ddG > ddI. These compounds were evaluated in vitro for ability to suppress the infectivity, replication, and cytopathic effect of HIV. 2-Amino-6-fluoro-, 2-amino-6-chloro-, and 6-fluoro-ddP exhibited a potent activity against HIV comparable to that of ddI or ddG and completely blocked the infectivity of HIV without affecting the growth of target cells. The comparative order of in vitro anti-HIV activity was 2-amino-6-fluoro, 2-amino-6-chloro, 6-fluoro > 2-amino-6-bromo > 2-amino-6-iodo, 6-chloro > 6-bromo > 6-iodo. These compounds also exhibited potent in vitro activity against HIV-2 and 3'-azido-3'-deoxythymidine-resistant HIV-1 variants. All 2-amino-6-halo-ddPs and 6-halo-ddPs were substrates for adenosine deaminase (ADA) and were converted to ddG or ddI, respectively. In the presence of the potent ADA inhibitor 2'-deoxycoformycin, 6-halo-substituted ddPs failed to exert an in vitro antiretroviral effect. These dideoxypurine nucleoside analogues represent a new class of lipophilic prodrugs of ddG and ddI that possess the potential for more effective therapy of HIV-induced neurologic disorders.
Nucleoside compounds of the formula
wherein:
B is guanine, adenine, thymine, uracil, cytosine, hypoxanthine, xanthine, 5-methylcytosine, 4-ethoxy-5-methyl-2-oxo-pyrimidine, 4-isopropoxy-5-methyl-2-oxo-pyrimidine, or 5-methyl-2-oxo-pyrimidine;
X isHorF;
Y is H, OH, OCH3 or F; and
Z is
where n is zero, one, or three and both R are hydrogen or lower alkyl; or
Y and Z together form a cyclic phosphate ester; and the pharmaceutically acceptable esters, ethers and salts thereof, have been found to have potent antiviral activity with a high therapeutic ratio.
式中的核苷化合物
其中
B 是鸟嘌呤、腺嘌呤、胸腺嘧啶、尿嘧啶、胞嘧啶、次黄嘌呤、黄嘌呤、5-甲基胞嘧啶、4-乙氧基-5-甲基-2-氧代嘧啶、4-异丙氧基-5-甲基-2-氧代嘧啶或 5-甲基-2-氧代嘧啶;
X 是 H 或 F;
Y 是 H、OH、OCH3 或 F;以及
Z 是
其中 n 为 0、1 或 3,两个 R 均为氢或低级烷基;或
Y 和 Z 共同形成环磷酸酯;已发现这些药学上可接受的酯、醚和盐具有很强的抗病毒活性和很高的治疗比例。
MURAKAMI, KUNICHIKA;SHIRASAKA, TAKUMA;YOSHIOKA, HIDETOSHI;KOJIMA, EIJI;AO+, J. MED. CHEM., 34,(1991) N, C. 1606-1612